These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2293405)

  • 1. Factors influencing plasma level/dose ratios of carbamazepine and its major metabolites in epileptic children.
    Hartley R; Lucock MD; Ng PC; Forsythe WI; McLain B; Bowmer CJ
    Ther Drug Monit; 1990 Sep; 12(5):438-44. PubMed ID: 2293405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children.
    Hartley R; Forsythe WI; McLain B; Ng PC; Lucock MD
    Clin Pharmacokinet; 1991 Mar; 20(3):237-46. PubMed ID: 2025982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between carbamazepine-diol, carbamazepine-epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: the influence of age, sex, and comedication.
    Svinarov DA; Pippenger CE
    Ther Drug Monit; 1996 Dec; 18(6):660-5. PubMed ID: 8946662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of sex, age, weight, and carbamazepine dose on serum concentrations, concentration ratios, and level/dose ratios of carbamazepine and its metabolites.
    Liu H; Delgado MR
    Ther Drug Monit; 1994 Oct; 16(5):469-76. PubMed ID: 7846744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive study of the relation between serum concentrations, concentration ratios, and level/dose ratios of carbamazepine and its metabolites with age, weight, dose, and clearances in epileptic children.
    Liu H; Delgado MR
    Epilepsia; 1994; 35(6):1221-9. PubMed ID: 7988515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication.
    Rambeck B; May T; Juergens U
    Ther Drug Monit; 1987 Sep; 9(3):298-303. PubMed ID: 3672573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing plasma concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic children and adults.
    Lanchote VL; Bonato PS; Campos GM; Rodrigues I
    Ther Drug Monit; 1995 Feb; 17(1):47-52. PubMed ID: 7725376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing simultaneous concentrations of total and free carbamazepine and carbamazepine-10, 11-epoxide in serum of children with epilepsy.
    Elyas AA; Patsalos PN; Agbato OA; Brett EM; Lascelles PT
    Ther Drug Monit; 1986; 8(3):288-92. PubMed ID: 3750372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of polytherapy on the relationships between serum carbamazepine and its metabolites in epileptic children.
    Liu H; Delgado MR
    Epilepsy Res; 1994 Mar; 17(3):257-69. PubMed ID: 8013448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Problem of spurious correlation in the evaluation of steady-state carbamazepine levels using metabolite data.
    van Belle G; Friel PN
    Ther Drug Monit; 1986; 8(2):177-83. PubMed ID: 3726931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbamazepine-10,11-diol steady-state serum levels and renal excretion during carbamazepine therapy in adults and children.
    Bourgeois BF; Wad N
    Ther Drug Monit; 1984; 6(3):259-65. PubMed ID: 6506133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbamazepine drug interactions: the influence of concurrent drug therapy on serum concentrations of carbamazepine and its epoxide metabolite.
    Wang RB; Liu LT; Yiu CH; Chang TY
    Zhonghua Yi Xue Za Zhi (Taipei); 1990 Apr; 45(4):222-32. PubMed ID: 2168269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of intraindividual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism.
    Tomson T; Svensson JO; Hilton-Brown P
    Ther Drug Monit; 1989 Sep; 11(5):533-9. PubMed ID: 2815227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of phenobarbital and phenytoin with carbamazepine and its metabolites' concentrations, concentration ratios, and level/dose ratios in epileptic children.
    Liu H; Delgado MR
    Epilepsia; 1995 Mar; 36(3):249-54. PubMed ID: 7614908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients.
    MacKichan JJ; Duffner PK; Cohen ME
    Br J Clin Pharmacol; 1981 Jul; 12(1):31-7. PubMed ID: 7248139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Free and total plasma concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients: diurnal fluctuations and relationship with side effects.
    Riva R; Contin M; Albani F; Perucca E; Ambrosetto G; Gobbi G; Cortelli P; Procaccianti G; Baruzzi A
    Ther Drug Monit; 1984; 6(4):408-13. PubMed ID: 6542700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbamazepine and carbamazepine-10,11-epoxide serum concentrations in epileptic children.
    Furlanut M; Montanari G; Bonin P; Casara GL
    J Pediatr; 1985 Mar; 106(3):491-5. PubMed ID: 3973787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of metabolic parameters of carbamazepine in the therapeutic monitoring of Tunisian patients with epilepsy.
    Chbili C; Hassine A; Ben Amor S; Nouira M; Ben Ammou S; Saguem S
    Rev Neurol (Paris); 2016; 172(4-5):313-7. PubMed ID: 27062293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism.
    Macphee GJ; Butler E; Brodie MJ
    Epilepsia; 1987; 28(3):286-94. PubMed ID: 3582293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients.
    Nakajima Y; Saito Y; Shiseki K; Fukushima-Uesaka H; Hasegawa R; Ozawa S; Sugai K; Katoh M; Saitoh O; Ohnuma T; Kawai M; Ohtsuki T; Suzuki C; Minami N; Kimura H; Goto Y; Kamatani N; Kaniwa N; Sawada J
    Eur J Clin Pharmacol; 2005 Mar; 61(1):25-34. PubMed ID: 15692831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.